Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRhythm HoldingsIRTC +1.31%79 3-Year EPS without NRI Growth Rate is 31.30% as of Jun. 2026. GuruFocus rates IRTC with a GF Score™ of 79/100 and a GF Value™ of $154.81 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 662 Medical Devices & Instruments companies, iRhythm Holdings ranks better than 78.1% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 31.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 6.40% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -1.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of iRhythm Holdings was 31.30% per year. The lowest was -33.40% per year. And the median was -6.90% per year.
iRhythm Holdings (NAS:IRTC) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
iRhythm Holdings 3-Year EPS without NRI Growth Rate Related Terms
IRTC vs ITGR, LIVN, HAE: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, iRhythm Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRhythm Holdings 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where iRhythm Holdings's 3-Year EPS without NRI Growth Rate falls into.
iRhythm Holdings 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 31.30% mean?
iRhythm Holdings (IRTC) has a 3-Year EPS without NRI Growth Rate of 31.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for iRhythm Holdings and its competitors. According to the industry distribution chart, iRhythm Holdings ranks #145 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 21.9%.
Is iRhythm Holdings' 3-Year EPS without NRI Growth Rate too high?
iRhythm Holdings' current 3-Year EPS without NRI Growth Rate is 31.30%. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. iRhythm Holdings' value of 31.30% is 288.8% above this industry median. Based on the distribution chart, iRhythm Holdings ranks #145 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, iRhythm Holdings has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRhythm Holdings' 3-Year EPS without NRI Growth Rate compare to ITGR and LIVN?
According to the Medical Devices & Instruments industry distribution chart, iRhythm Holdings ranks #145 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places iRhythm Holdings in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. iRhythm Holdings' value of 31.30% is 288.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRhythm Holdings's current 3-Year EPS without NRI Growth Rate of 31.30% is 288.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for iRhythm Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRhythm Holdings's current 3-Year EPS without NRI Growth Rate is 31.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRhythm Holdings stock overvalued right now?
Based on GuruFocus' analysis, iRhythm Holdings (IRTC) is currently considered Modestly Undervalued. The stock's GF Value™ is $154.81, compared to a current price of $110.74 — trading 28.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 31.30% and 288.8% above the Medical Devices & Instruments industry median of 8.05. iRhythm Holdings' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For iRhythm Holdings (IRTC), the current 3-Year EPS without NRI Growth Rate is 31.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRhythm Holdings (IRTC) Overvalued in 2026?
Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued.
The current stock price of $110.74 is trading 28.5% below its estimated GF Value™ of $154.81.
GuruFocus considers iRhythm Holdings to be Modestly Undervalued.
Key valuation signals for IRTC:
3-Year EPS without NRI Growth Rate: 31.30%
GF Value™: $154.81 vs. price of $110.74 (28.5% below fair value)
Industry Position: 288.8% above the Medical Devices & Instruments median (#145 of 662)
No single metric tells the full story. See the IRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
79GF Score
Get the complete analysis for IRTC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRTC has been successfully added to your 
